In the BioHarmony Drug Report Database
Zanubrutinib
Brukinsa (zanubrutinib) is a small molecule pharmaceutical. Zanubrutinib was first approved as Brukinsa on 2019-11-14. It is used to treat mantle-cell lymphoma in the USA. It is known to target tyrosine-protein kinase BTK. Brukinsa’s patents are valid until 2037-08-15 (FDA).
Trade Name
|
Brukinsa |
|---|---|
Common Name
|
zanubrutinib |
ChEMBL ID
|
CHEMBL3936761 |
Indication
|
mantle-cell lymphoma |
Drug Class
|
Tyrosine kinase inhibitors: Bruton's (Btk) inhibitors |
Image (chem structure or protein)